-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Expands By 30.6%
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Expands By 30.6%
PureTech Health plc (NASDAQ:PRTC – Get Rating) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 4,700 shares, a growth of 30.6% from the July 31st total of 3,600 shares. Based on an average daily trading volume, of 4,100 shares, the days-to-cover ratio is currently 1.1 days.
Analyst Ratings Changes
PRTC has been the subject of several research reports. Piper Sandler raised their target price on PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a research note on Thursday, August 25th. SVB Leerink decreased their target price on PureTech Health from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, June 15th.
Get PureTech Health alerts:Institutional Investors Weigh In On PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. grew its stake in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company's stock.
PureTech Health Trading Down 4.5 %
PRTC stock traded down $1.35 during trading hours on Tuesday, hitting $28.65. 200 shares of the stock traded hands, compared to its average volume of 5,304. PureTech Health has a one year low of $18.15 and a one year high of $54.39. The company has a current ratio of 2.54, a quick ratio of 2.22 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $25.13 and a 200 day simple moving average of $25.40.About PureTech Health
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Featured Stories
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
- MarketBeat Podcast: The Time For Cloud Stocks May Be Now
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
PureTech Health plc (NASDAQ:PRTC – Get Rating) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 4,700 shares, a growth of 30.6% from the July 31st total of 3,600 shares. Based on an average daily trading volume, of 4,100 shares, the days-to-cover ratio is currently 1.1 days.
純易達健康公司(納斯達克：PRTC-GET評級)是空頭股數8月份大幅增長的目標。截至8月15日，空頭股數共有4,700股，較7月31日的3,600股增長30.6%。以日均成交量4,100股計算，目前天數與回補比率為1.1天。
Analyst Ratings Changes
分析師評級發生變化
PRTC has been the subject of several research reports. Piper Sandler raised their target price on PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a research note on Thursday, August 25th. SVB Leerink decreased their target price on PureTech Health from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, June 15th.
PRTC一直是幾份研究報告的主題。派珀·桑德勒在8月25日週四的一份研究報告中將其對PureTech Health的目標價從37.00美元上調至44.00美元，並給予該公司“增持”評級。SVB Leerink在6月15日(週三)的一份研究報告中將PureTech Health的目標價從70.00美元下調至66.00美元，併為該公司設定了“跑贏大盤”的評級。
Institutional Investors Weigh In On PureTech Health
機構投資者看好PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. grew its stake in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company's stock.
一家對衝基金最近增持了PureTech Health股票。根據AWM投資公司在提交給美國證券交易委員會的最新Form 13F文件中的數據，第二季度該公司在PureTech Health Plc(納斯達克代碼：PRTC-GET評級)的股票增加了2,100.0%。該基金持有66萬股該公司股票，在此期間又購買了63萬股。截至最近提交的美國證券交易委員會申請文件，AWM Investment Company Inc.持有PureTech Health約2.32%的股份，價值2,513,000美元。機構投資者和對衝基金持有該公司2.32%的股票。
PureTech Health Trading Down 4.5 %
PureTech Health交易下跌4.5%
About PureTech Health
關於PureTech Health
(Get Rating)
(獲取評級)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家臨牀階段的生物治療公司，在美國發現、開發和銷售治療炎症、纖維化和免疫、頑固性癌症、淋巴和胃腸道、神經和神經心理以及其他疾病的藥物。該公司提供靶向M膽鹼乙酰膽鹼受體的KarXT，用於治療阿爾茨海默病的精神分裂症和精神病；用於治療雄激素性脱髮、上皮老化和其他疾病的再生生物學平臺；用於治療慢性和急性炎症性疾病的免疫調節平臺；用於從人體微生物羣中分離出基於特定細菌羣的口服療法；以及用於治療與抑鬱症、多發性硬化症、COVID後和ICU以及癌症相關疾病相關的認知功能障礙的療法。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
- MarketBeat Podcast: The Time For Cloud Stocks May Be Now
- 免費獲取StockNews.com關於PureTech Health(PRTC)的研究報告
- 減震器：顛簸時代的3只低波動率紅利股票
- 零售業：第二季度收益的贏家和輸家
- Targa能否繼續反彈以實現其價格目標？
- 在拒絕了AppLovin的報價後，Unity Software準備好重整旗鼓了嗎？
- MarketBeat播客：雲股票的時代可能就是現在
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
獲得PureTech HealthDaily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對PureTech Health和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧